Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 1/20 | 0.61 |
| ▸ | DDAH1 | O94760 | 1/20 | 0.51 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.48 |
| ▸ | RAB9A | P51151 | 5/20 | 0.48 |
| ▸ | LMNA | P02545 | 3/20 | 0.48 |
| ▸ | HTT | P42858 | 2/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | GFER | P55789 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | TSHR | P16473 | 2/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.45 |
| ▸ | HPGD | P15428 | 2/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 5/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22292426 | 0.84 | ALDH1A1 (0.48) | ELANEDDAH1ADRA2CALDH1A1SMN1; SMN2 | |
| SCHEMBL15003936 | 0.83 | DDAH1 (0.53) | DDAH1ADRA2CALDH1A1SMN1; SMN2KMT2A | |
| SCHEMBL18013090 | 0.83 | ALDH1A1 (0.50) | ELANEDDAH1ADRA2CALDH1A1SMN1; SMN2 | |
| SCHEMBL4188069 | 0.82 | DDAH1 (0.59) | DDAH1ADRA2CALDH1A1SMN1; SMN2KMT2A | |
| SCHEMBL18776132 | 0.79 | DDAH1 (0.53) | DDAH1ADRA2CALDH1A1SMN1; SMN2KMT2A | |
| SCHEMBL303847 | 0.79 | ELANE (0.58) | ELANEDDAH1ADRA2CALDH1A1SMN1; SMN2 | |
| SCHEMBL31155591 | 0.79 | ELANE (0.58) | ELANEDDAH1ADRA2CALDH1A1SMN1; SMN2 | |
| SCHEMBL28366757 | 0.78 | DDAH1 (0.59) | DDAH1ADRA2CALDH1A1SMN1; SMN2KMT2A | |
| SCHEMBL18013088 | 0.77 | DDAH1 (0.59) | DDAH1ADRA2CALDH1A1SMN1; SMN2KMT2A | |
| SCHEMBL16256319 | 0.77 | SMN1; SMN2 (0.48) | DDAH1ADRA2CALDH1A1SMN1; SMN2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230242565-A1 | Macrolides with Modified Desosamine Sugars and Uses Thereof | ZIKANI THERAPEUTICS, INC. | 2023-08-03 | — | — | US | disclosed |
| US-20230242565-A1 | Macrolides with Modified Desosamine Sugars and Uses Thereof | ZIKANI THERAPEUTICS, INC. | 2023-08-03 | — | — | US | disclosed |
| US-11673910-B2 | Macrolides with modified desosamine sugars and uses thereof | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2023-06-13 | — | — | US | disclosed |
| US-11673910-B2 | Macrolides with modified desosamine sugars and uses thereof | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2023-06-13 | — | — | US | disclosed |
| US-20210228550-A1 | Inhibiting Germination of Clostridium Perfringens Spores to Reduce Necrotic Enteritis | THE BOARD OF REGENTS OF THE NEVADA SYSTEM OF HIGHER EDUCATION ON BEHALF OF THE UNIVERSITY OF NEVADA, LAS VEGAS | 2021-07-29 | — | — | US | disclosed |
| US-11008358-B2 | Synthesis of desosamines | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2021-05-18 | — | — | US | disclosed |
| US-10945996-B2 | Inhibiting germination of clostridium perfringens spores to reduce necrotic enteritis | THE BOARD OF REGENTS OF THE NEVADA SYSTEM OF HIGHER EDUCATION ON BEHALF OF THE UNIVERSITY OF NEVADA, LAS VEGAS (US) | 2021-03-16 | — | — | US | disclosed |
| US-20200347087-A1 | SYNTHESIS OF DESOSAMINES | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2020-11-05 | — | — | US | disclosed |
| US-10729738-B2 | Hindered disulfide drug conjugates | GENENTECH, INC. (US) | 2020-08-04 | — | — | US | disclosed |
| US-10544182-B2 | Synthesis of desosamines | Presidents and Fellow of Harvard College (US) | 2020-01-28 | — | — | US | disclosed |
| US-20190209531-A1 | Inhibiting Germination of Clostridium Perfringens Spores to Reduce Necrotic Enteritis | THE BOARD OF REGENTS OF THE NEVADA SYSTEM OF HIGHER EDUCATION ON BEHALF OF THE UNIVERSITY OF NEVADA, LAS VEGAS | 2019-07-11 | — | — | US | disclosed |
| US-20180111956-A1 | SYNTHESIS OF DESOSAMINES | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2018-04-26 | — | — | US | disclosed |
| US-20180111956-A1 | SYNTHESIS OF DESOSAMINES | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2018-04-26 | — | — | US | disclosed |
| US-20180000793-A1 | Inhibiting Germination of Clostridium Perfringens Spores to Reduce Necrotic Enteritis | ABEL-SANTOS ERNESTO (US) | 2018-01-04 | — | — | US | disclosed |
| WO-2016127102-A2 | INHIBITING GERMINATION OF CLOSTRIDIUM PERFRINGENS SPORES TO REDUCE NECROTIC ENTERITIS | ABEL-SANTOS ERNESTO (US) | 2016-08-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11008358-B2 | Synthesis of desosamines | NANS, GALE, FUT6 | ELANE 1947/4885DDAH1 266/4885ADRA2C 2954/4885 |
| US-11673910-B2 | Macrolides with modified desosamine sugars and uses thereof | FUT6, DDOST, MGAM | ELANE 2898/4885DDAH1 3763/4885ADRA2C 4438/4885 |
| US-10945996-B2 | Inhibiting germination of clostridium perfringens spores to reduce necrotic enteritis | CASP3, SI, PYCARD | ELANE 158/4885DDAH1 2270/4885ADRA2C 4119/4885 |
| US-10544182-B2 | Synthesis of desosamines | NANS, GALE, FUT6 | ELANE 1947/4885DDAH1 266/4885ADRA2C 2954/4885 |
| US-20180111956-A1 | SYNTHESIS OF DESOSAMINES | NANS, GALE, FUT6 | ELANE 1947/4885DDAH1 266/4885ADRA2C 2954/4885 |
| US-20190209531-A1 | Inhibiting Germination of Clostridium Perfringens Spores to Reduce Necrotic Enteritis | CASP3, SI, PYCARD | ELANE 158/4885DDAH1 2270/4885ADRA2C 4119/4885 |
| US-20210228550-A1 | Inhibiting Germination of Clostridium Perfringens Spores to Reduce Necrotic Enteritis | CASP3, SI, PYCARD | ELANE 158/4885DDAH1 2270/4885ADRA2C 4119/4885 |
| US-20200347087-A1 | SYNTHESIS OF DESOSAMINES | NANS, GALE, FUT6 | ELANE 1947/4885DDAH1 266/4885ADRA2C 2954/4885 |
| US-10729738-B2 | Hindered disulfide drug conjugates | STS, TST, SCLY | ELANE 2503/4885DDAH1 659/4885ADRA2C 2968/4885 |
| US-20230242565-A1 | Macrolides with Modified Desosamine Sugars and Uses Thereof | FUT6, DDOST, MGAM | ELANE 2898/4885DDAH1 3763/4885ADRA2C 4438/4885 |
| US-20180000793-A1 | Inhibiting Germination of Clostridium Perfringens Spores to Reduce Necrotic Enteritis | CASP3, SI, PYCARD | ELANE 158/4885DDAH1 2270/4885ADRA2C 4119/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.